Dernières nouvelles pour Steakholder Foods (NASDAQ:STKH) Stock

Steakholder Foods

Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.

<p>Truist Securities  analyst Michael Ciarmoli   maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Hold and lowers the price target from $356 to $338.</p>


News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Curtiss-Wright, Lowers Price Target to $338

<p>Wells Fargo  analyst Michael Brown   maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Overweight and raises the price target from $58 to $62.</p>


Wells Fargo Maintains Overweight on TPG, Raises Price Target to $62

<p>Truist Securities  analyst Michael Ciarmoli   maintains Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Buy and lowers the price target from $579 to $554.</p>


Truist Securities Maintains Buy on Lockheed Martin, Lowers Price Target to $554

<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="678" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-1024x678.jpg" alt="" class="wp-image-15509" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-1024x678.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-300x199.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap-768x509.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011117/IonQ-Ion-MGT-Trap.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Trapped-ion computing processor. Used with permission: IonQ.</strong></p>
<p>Quantum computing has arrived. IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leading commercial quantum computing and networking company, is shipping quantum computers and networks, growing at an almost 100% YoY pace, as well as selling and winning deals at over $44 a share. Ironically, it seems that the market hasn't fully grasped that yet. They're still thinking of massive lab prototypes and expensive sub-Kelvin dilution refrigerators, while IonQ is bringing live systems to paying customers worldwide.</p>
<h2 class="wp-block-heading"><strong>Selling full quantum systems, while scaling from the cloud to the planet</strong></h2>
<p>IonQ systems run on AWS Braket, Azure Quantum and Google Quantum AI Cloud. That makes at least three major public clouds. No other quantum vendor matches that reach. Through its strategic organic and inorganic expansion, IonQ operates in Asia, EU, Canada, UK and America. That global network footprint isn't experimental. The company&#8217;s commercial infrastructure leverages hyperscalers, telecom and defense-adjacent applications.</p>
<p>And they didn't stumble into this, they systematically assembled it. They <a href="https://ionq.com/news/ionq-completes-acquisition-of-lightsynq-accelerating-quantum-computing-and">bought Lightsynq in June</a> to further expand their photonic interconnect and quantum memory capabilities. "With this acquisition, we're accelerating our development timeline to fault tolerant quantum computers and long distance networking capabilities," CEO Niccolo de Masi said during an exclusive interview.</p>
<p>The acquired Lightsync technology allows IonQ to provide optimized compute capabilities over thousands of kilometers. He said Lightsynq latency shifts from about 55 milliseconds to two seconds, which is a 97% improvement, letting entanglement persist long enough for even more complex real-world applications to run. That's not hypothetical puffery, it's architectural muscularity.</p>
<p>They also inked a <a href="https://ionq.com/news/ionq-announces-usd22m-deal-with-epb-establishing-chattanooga-tennessee-as">$22 million deal with EPB </a>to establish a quantum hub in Chattanooga offering Forte Enterprise and networking training for grid optimization. That marks the first U.S. quantum computing and networking center complete with a new IonQ office.</p>
<h2 class="wp-block-heading"><strong>This is an acquisition spree with strategy</strong></h2>
<p>In addition to buying Lightsynq, IonQ is now the majority shareholder of <a href="https://ionq.com/news/ionq-to-acquire-id-quantique-enter-into-strategic-partnership-with-sk">ID Quantique</a> to beef up their Swiss-grade quantum networking capabilities. They announced the <a href="https://ionq.com/news/ionq-announces-plans-for-first-space-based-quantum-key-distribution-network">Capella Space</a> acquisition to take quantum key distribution systems into orbit, creating a secure satellite-ground quantum internet. Most recently they agreed to <a href="https://ionq.com/news/ionq-announces-agreement-to-acquire-oxford-ionics-accelerating-path-to-pioneering">buy Oxford Ionics for $1.075 billion</a>, gaining OI&#8217;s complementary ion-trap breakthrough tech and UK R&amp;D depth.</p>
<p>Add it up. They're assembling compute, memory, networking, satellite and cloud access into one commercial platform. That's a full tech stack, vertically integrated. IonQ is one of the biggest, if not the biggest, public-quantum movers by acquisition count with an IP portfolio of almost 1000 owned and controlled patents.</p>
<h2 class="wp-block-heading"><strong>AQ is the metric that actually matters</strong></h2>
<p>IonQ talks algorithmic qubits, AQ, rather than inflated raw qubit counts. Their Forte and Forte Enterprise quantum systems hit AQ 36. While the next-gen Tempo quantum systems will target AQ 64 by the end of 2025.</p>
<p>"AQ 64 is an important milestone for our industry. Even a data center packed with classical GPUs couldn't keep up with a single AQ 64 machine when trying to exactly simulate its quantum circuits. Especially for small-scale versions of factoring, decryption, optimization or linear-algebra workloads,&#8221; explained  de Masi.</p>
<p>AQ signals usable compute power, not just hardware specs. It integrates error rates, fidelity, connectivity and circuit depth. It's performance that users can build with. And they're already delivering. </p>
<p>Software simulation leader Ansys saw a <a href="https://www.iotworldtoday.com/quantum/medical-engineering-simulations-accelerated-12-by-quantum-computer">12% speed-up on heart-pump simulations</a>, and IonQ&#8217;s work with AstraZeneca, AWS and Nvidia <a href="https://thequantuminsider.com/2025/06/09/ionq-speeds-quantum-accelerated-drug-development-application-in-partnership-with-astrazeneca-aws-and-nvidia/">cut drug-discovery interference times by 20x</a>. These are real customer benchmarks.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-1024x683.jpg" alt="" class="wp-image-15511" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-1024x683.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-300x200.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1-768x512.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011514/Nicco-de-Masi_022625_001-Edit-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>Niccolo de Masi, IonQ CEO and Cambridge-trained physicist. Used with permission: IonQ.</p>
<h2 class="wp-block-heading"><strong>Quantum networking is the subplot few are pricing in</strong></h2>
<p>Compute grabs headlines. Networking unlocks scale. IonQ leads here. "We are the only public quantum networking company in the world," de Masi said.</p>
<p>IonQ is building quantum repeaters via Lightsynq. Capella Space extends links to satellites and back to earth. EPB in Tennessee gives grid-scale metropolitan hubs. ID Quantique expands the quantum networking capabilities and backbone. That adds up to a real quantum internet. Encryption, finance, defense and satellite operations are all sectors IonQ is positioning to serve through secure networks.</p>
<p>"We have an exceptional opportunity to accelerate our vision for the quantum internet through our announced acquisitions of LightSynq and Capella," De Masi said. That's ambition backed by capital and hardware.</p>
<h2 class="wp-block-heading"><strong>Miniaturization and energy-efficient design</strong></h2>
<p>Quantum systems usually require bulky cryogenic setups. IonQ has been pushing room-temperature, vacuum-less parts that reduce weight, cost and power use. They're moving toward modular, replaceable components that match data center readiness. It's also about building a compute, networking and applications ecosystem smartly, not just building massive server farms with extreme climate controls and state-mandated, co-located power stations.</p>
<p>"This is the quantum computing industry, not the quantum construction business. Never in the history of computing has anything other than smaller and cheaper won. Additionally, quantum computers run on a fraction of the electricity of classical supercomputers, and <a href="https://theconversation.com/could-energy-efficiency-be-quantum-computers-greatest-strength-yet-191989">in some instances quantum is 100x more energy efficient</a> than traditional compute, " de Masi said.</p>
<p>That's not theoretical. It's operational.</p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-1024x576.jpg" alt="" class="wp-image-15513" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-1024x576.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3-768x432.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/09011643/Tori-Carey-in-CP-3.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>IonQ engineer holding a test wafer of dozens of quantum processors. Used with permission: IonQ.</p>
<h2 class="wp-block-heading"><strong>Financial strength and capital to execute</strong></h2>
<p>IonQ recently <a href="https://finance.yahoo.com/news/ionq-announces-pricing-1-0-125500938.html">priced a $1 billion equity raise</a> at $55.49 a share, that&#8217;s more than a 25% premium over the prior market closing price, lifting cash to $1.68 billion. That's one of the largest single-investor deals in quantum history. <a href="https://finance.yahoo.com/news/ionq-price-target-raised-55-122507534.html">Benchmark</a> and <a href="https://investorsobserver.com/news/stock-update/priced-for-the-future-ionq-can-grow-into-quantum-premium-analyst-says/#:~:text=That's%20one%20of%20the%20main,capitalization%20of%20approximately%20$11.5%20billion.">Cantor</a> called it confirmation of IonQ's differentiated commercial model across hardware, services and applications.</p>
<p>While still pursuing profitability, its Q1 revenue came in above guidance. Cash sat at nearly $750 million. Hyundai, Airbus, Air Force Research Lab, EPB, University of Maryland and AWS are all paying or paid to use IonQ's the tech. Based on IonQ's earnings disclosures and expansion activity, the capital appears targeted toward scaling compute, networking and commercial systems.</p>
<h2 class="wp-block-heading"><strong>The entire company is its competitive moat</strong></h2>
<p>IonQ is unique within the pure-play quantum computing space. Acquisitions, cloud reach, engineering, hardware, networking, satellite and workforce hubs. Patent depth. Customer results. Cash. Its technical roadmap.</p>
<p>"Every day we get up in the morning knowing that we can impact every area of applied science," De Masi told me. "Whether it's drug discovery or defense and intelligence or logistics or material science, we impact everything."</p>
<p>IonQ's execution speaks louder than its pure-play quantum computing competitors. That's what sets them apart.</p>
<h2 class="wp-block-heading">Do your own research, you&#8217;ll see what the &#8220;smart money&#8221; sees</h2>
<p>These are obviously personal opinions; not financial advice. Anyone considering investing in any asset needs to do their own research and understand the risks associated with emerging tech such as quantum computing. While I no longer own any shares of IonQ, when I sold my entire stake in mid-December 2024 I turned a 340% profit. That was the best performing equity asset in my portfolio. And based on all the publicly available information about this company; it&#8217;s still a banger with room to run.</p>
<p>The latest sale to <a href="https://finance.yahoo.com/news/ionq-announces-pricing-1-0-125500938.html">Heights Capital Management of more than 14 million IonQ shares</a> at a 25% markup with the seven-year option of buying another 36 million shares at $99.88 each is a resounding vote of confidence from Wall Street sharps regarding IonQ&#8217;s potential upside.</p>
<p>Quantum isn't five years away. It's crossing into reality with commercial contracts, live networks and satellite integration underway. IonQ is the stock that reflects that. Not early-stage theory. Not hype. Just results.</p>



Equities

Long Ideas

Opinion

Tech

IONQ

Why IonQ Is My Top Stock Pick For 2025

<p>Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore").</p>
<p>According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of the merger agreement proposal.</p>
<p>As previously announced on March 6, 2025, under the terms of the Merger Agreement, WBA shareholders will receive $11.45 per share in cash at closing, and one non-transferable Divested Asset Proceeds Right to receive up to an additional $3.00 in cash per share from the future monetization of WBA's debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses.</p>
<p>WBA expects to close the transaction in the third or fourth quarter of calendar year 2025, subject to customary closing conditions, including the receipt of required regulatory approvals.</p>


Walgreens Boots Alliance Shareholders Approve Acquisition Of The Company By Entities Affiliated With Sycamore Partners Management; Transaction Expected To Close in Q3 or Q4 Of CY25

<p>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-14. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Simulations Plus will report an <strong>earnings per share</strong> (EPS) of $0.26.</p>
<p>The market awaits Simulations Plus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Historical Earnings Performance</h3>
<p>Last quarter the company beat EPS by $0.05, which was followed by a 7.83% increase in the share price the next day.</p>
<p>Here's a look at Simulations Plus's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.26</td>
<td>0.17</td>
<td>0.03</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.17</td>
<td>0.06</td>
<td>0.19</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-7.000000000000001%</td>
<td>-9.0%</td>
<td>-15.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242497_0.png" alt="eps graph" /></p>
<h3>Simulations Plus Share Price Analysis</h3>
<p>Shares of Simulations Plus were trading at $17.57 as of July 10. Over the last 52-week period, shares are down 58.91%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Analysts' Take on Simulations Plus</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Simulations Plus.</p>
<p>The consensus rating for Simulations Plus is Buy, derived from 3 analyst ratings. An average one-year price target of $33.67 implies a potential 91.63% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Health Catalyst, Definitive Healthcare and OptimizeRx, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Health Catalyst, with an average 1-year price target of $6.0, suggesting a potential 65.85% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Definitive Healthcare, with an average 1-year price target of $3.4, suggesting a potential 80.65% downside.</li>
<li>Analysts currently favor an Buy trajectory for OptimizeRx, with an average 1-year price target of $14.17, suggesting a potential 19.35% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>In the peer analysis summary, key metrics for Health Catalyst, Definitive Healthcare and OptimizeRx are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simulations Plus</td>
<td>Buy</td>
<td>22.55%</td>
<td>$13.13M</td>
<td>1.64%</td>
</tr>
<tr>
<td>Health Catalyst</td>
<td>Buy</td>
<td>6.28%</td>
<td>$36.23M</td>
<td>-6.40%</td>
</tr>
<tr>
<td>Definitive Healthcare</td>
<td>Neutral</td>
<td>-6.76%</td>
<td>$43.76M</td>
<td>-27.95%</td>
</tr>
<tr>
<td>OptimizeRx</td>
<td>Buy</td>
<td>11.37%</td>
<td>$13.34M</td>
<td>-1.89%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Simulations Plus ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating. However, it has the lowest Return on Equity compared to its peers.</p>
<h3>All You Need to Know About Simulations Plus</h3>
<p>Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.</p>
<h3>Key Indicators: Simulations Plus's Financial Health</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Simulations Plus displayed positive results in 3 months. As of 28 February, 2025, the company achieved a solid revenue growth rate of approximately <strong>22.55%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Simulations Plus's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>13.7%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.64%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Simulations Plus's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.54%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Simulations Plus's debt-to-equity ratio is below the industry average at <strong>0.0</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/SLP/earnings"><strong>To track all earnings releases for Simulations Plus visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

A Look Ahead: Simulations Plus's Earnings Forecast

<p>Equity Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQBK#NYSE">EQBK</a>) is preparing to release its quarterly earnings on Monday, 2025-07-14. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Equity Bancshares to report an <strong>earnings per share</strong> (EPS) of $0.89.</p>
<p>The market awaits Equity Bancshares's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 1.25% increase in the share price the following trading session.</p>
<p>Here's a look at Equity Bancshares's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.83</td>
<td>0.92</td>
<td>0.99</td>
<td>0.92</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.85</td>
<td>1.04</td>
<td>1.31</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>2.0%</td>
<td>2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242487_0.png" alt="eps graph" /></p>
<h3>Performance of Equity Bancshares Shares</h3>
<p>Shares of Equity Bancshares were trading at $43.41 as of July 10. Over the last 52-week period, shares are up 10.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/EQBK/earnings"><strong>To track all earnings releases for Equity Bancshares visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


EQBK

A Look at Equity Bancshares's Upcoming Earnings Report

<p>Truist Securities  analyst Michael Ciarmoli   maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Buy and raises the price target from $260 to $279.</p>


Truist Securities Maintains Buy on L3Harris Technologies, Raises Price Target to $279

<p>FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) is gearing up to announce its quarterly earnings on Monday, 2025-07-14. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that FB Financial will report an <strong>earnings per share</strong> (EPS) of $0.88.</p>
<p>The market awaits FB Financial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 1.97% drop in the share price on the subsequent day.</p>
<p>Here's a look at FB Financial's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.83</td>
<td>0.83</td>
<td>0.79</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.85</td>
<td>0.85</td>
<td>0.86</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>6.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242477_0.png" alt="eps graph" /></p>
<h3>Tracking FB Financial's Stock Performance</h3>
<p>Shares of FB Financial were trading at $47.39 as of July 10. Over the last 52-week period, shares are up 10.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FBK/earnings"><strong>To track all earnings releases for FB Financial visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For FB Financial

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Vertex Pharmaceuticals</strong>.</p>
<p>Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 11 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 9% of the investors opened trades with bullish expectations and 63% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $241,517 and 5, calls, for a total amount of $8,715,760.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $475.0 to $500.0 for Vertex Pharmaceuticals over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Vertex Pharmaceuticals stands at 1663.0, with a total volume reaching 3,306.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Vertex Pharmaceuticals, situated within the strike price corridor from $475.0 to $500.0, throughout the last 30 days.</p>
<h3>Vertex Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242469_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$92.0</td>
<td>$85.3</td>
<td>$86.0</td>
<td>$500.00</td>
<td>$3.4M</td>
<td>3.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$88.5</td>
<td>$86.1</td>
<td>$88.5</td>
<td>$500.00</td>
<td>$2.2M</td>
<td>3.3K</td>
<td>513</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$93.7</td>
<td>$88.2</td>
<td>$88.1</td>
<td>$500.00</td>
<td>$1.3M</td>
<td>3.3K</td>
<td>702</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$88.7</td>
<td>$84.6</td>
<td>$88.7</td>
<td>$500.00</td>
<td>$887.0K</td>
<td>3.3K</td>
<td>202</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$96.5</td>
<td>$87.1</td>
<td>$87.0</td>
<td>$500.00</td>
<td>$870.0K</td>
<td>3.3K</td>
<td>100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertex Pharmaceuticals</h3>
<p>Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.</p>
<p>Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Vertex Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 93,478, the VRTX's price is down by 0.0%, now at $479.53. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 24 days.</li>
</ul>
<h3>Professional Analyst Ratings for Vertex Pharmaceuticals</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $476.67.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $420.<br />
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $550.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Vertex Pharmaceuticals with a target price of $460. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vertex Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

VRTX

Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking

<p>Across the recent three months, 4 analysts have shared their insights on Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.25, a high estimate of $21.00, and a low estimate of $12.00. A decline of 24.99% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242467_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Vir Biotechnology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean McCutcheon</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vir Biotechnology. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vir Biotechnology compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Vir Biotechnology's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Vir Biotechnology's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VIR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vir Biotechnology analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Vir Biotechnology Better</h2>
<p>Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.</p>
<h3>Financial Milestones: Vir Biotechnology's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> Vir Biotechnology's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-96.5%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Vir Biotechnology's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-6742.75%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-11.03%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vir Biotechnology's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-8.94%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.09</strong>, Vir Biotechnology adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Vir Biotechnology Stands With Analysts

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>MARA Holdings</strong>.</p>
<p>Looking at options history for MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) we detected 12 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 33% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $95,489 and 10, calls, for a total amount of $421,940.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $6.0 to $25.0 for MARA Holdings over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in MARA Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to MARA Holdings's substantial trades, within a strike price spectrum from $6.0 to $25.0 over the preceding 30 days.</p>
<h3>MARA Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242464_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/11/25</td>
<td>$0.39</td>
<td>$0.38</td>
<td>$0.38</td>
<td>$19.00</td>
<td>$72.6K</td>
<td>42.1K</td>
<td>4.6K</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$6.1</td>
<td>$6.05</td>
<td>$6.05</td>
<td>$17.00</td>
<td>$60.5K</td>
<td>2.4K</td>
<td>102</td>
</tr>
<tr>
<td>MARA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$1.74</td>
<td>$1.72</td>
<td>$1.74</td>
<td>$18.00</td>
<td>$54.4K</td>
<td>1.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$0.94</td>
<td>$0.88</td>
<td>$0.96</td>
<td>$23.00</td>
<td>$47.9K</td>
<td>3.0K</td>
<td>20</td>
</tr>
<tr>
<td>MARA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.25</td>
<td>$3.15</td>
<td>$3.18</td>
<td>$17.00</td>
<td>$45.7K</td>
<td>5.0K</td>
<td>37</td>
</tr>
</tbody>
</table>
</p>
<h3>About MARA Holdings</h3>
<p>MARA Holdings Inc leverages digital asset compute to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value. The company also offers technology solutions to optimize data center operations, including next-generation liquid immersion cooling and firmware for bitcoin miners. It is focused on computing for, acquiring, and holding digital assets as a long-term investment.</p>
<p>Having examined the options trading patterns of MARA Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>MARA Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 9,471,531, the price of MARA is up 1.63% at $19.31. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>What Analysts Are Saying About MARA Holdings</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $19.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on MARA Holdings, maintaining a target price of $19. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for MARA Holdings, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


MARA

Unpacking the Latest Options Trading Trends in MARA Holdings

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>UnitedHealth Group</strong>.</p>
<p>Looking at options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) we detected 26 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 42% with bearish.</p>
<p>From the overall spotted trades, 11 are puts, for a total amount of $1,086,247 and 15, calls, for a total amount of $889,168.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $210.0 to $540.0 for UnitedHealth Group over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for UnitedHealth Group options trades today is 2706.65 with a total volume of 1,527.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for UnitedHealth Group's big money trades within a strike price range of $210.0 to $540.0 over the last 30 days.</p>
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242459_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$33.7</td>
<td>$33.4</td>
<td>$33.4</td>
<td>$300.00</td>
<td>$668.0K</td>
<td>3.4K</td>
<td align="right">207</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$61.0</td>
<td>$59.05</td>
<td>$59.56</td>
<td>$300.00</td>
<td>$119.0K</td>
<td>2.9K</td>
<td align="right">33</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/17/26</td>
<td>$51.25</td>
<td>$48.55</td>
<td>$50.58</td>
<td>$300.00</td>
<td>$111.2K</td>
<td>497</td>
<td align="right">0</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$18.1</td>
<td>$17.8</td>
<td>$17.8</td>
<td>$300.00</td>
<td>$89.0K</td>
<td>2.9K</td>
<td align="right">3</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$26.8</td>
<td>$26.15</td>
<td>$26.51</td>
<td>$330.00</td>
<td>$84.8K</td>
<td>4.4K</td>
<td align="right">181</td>
</tr>
</tbody>
</table>
</p>
<h3>About UnitedHealth Group</h3>
<p>UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.</p>
<p>After a thorough review of the options trading surrounding UnitedHealth Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of UnitedHealth Group</h3>
<ul>
<li>With a volume of 880,105, the price of UNH is up 0.13% at $299.88. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 18 days.</li>
</ul>
<h3>What The Experts Say On UnitedHealth Group</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $380.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for UnitedHealth Group, targeting a price of $337.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $418.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Buy rating on UnitedHealth Group with a target price of $385. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Market Whales and Their Recent Bets on UNH Options

<p>In the preceding three months, 6 analysts have released ratings for Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $161.33, a high estimate of $167.00, and a low estimate of $155.00. A decline of 3.4% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242458_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Hamilton Lane's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$162.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$155.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$161.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Ken Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$167.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$157.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hamilton Lane. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hamilton Lane compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Hamilton Lane's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HLNE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Hamilton Lane analyst ratings.</strong></a></p>
<h2>Delving into Hamilton Lane's Background</h2>
<p>Hamilton Lane Inc is a private market investment solutions provider in the United States. It works with its clients to conceive, structure, build out, manage and monitor portfolios of private markets funds and direct investments, and it helps them access a set of such investment opportunities around the world. The company offers a range of investment solutions across a range of private markets, including private equity, private credit, real estate, infrastructure, natural resources, growth equity, venture capital and impact. The company generate revenues mainly from management and advisory fees.</p>
<h3>Hamilton Lane: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Hamilton Lane showcased positive performance, achieving a revenue growth rate of <strong>12.06%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Hamilton Lane's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>25.51%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Hamilton Lane's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>7.39%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.08%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Hamilton Lane's debt-to-equity ratio is below the industry average. With a ratio of <b>0.51</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


HLNE

6 Analysts Assess Hamilton Lane: What You Need To Know

<p>Across the recent three months, 12 analysts have shared their insights on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $238.92, with a high estimate of $275.00 and a low estimate of $215.00. This current average has decreased by 3.17% from the previous average price target of $246.73. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242449_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Danaher. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$226.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$231.00</td>
<td>$258.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Danaher. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Danaher's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Danaher analyst ratings.</strong></a></p>
<h2>About Danaher</h2>
<p>In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.</p>
<h3>Key Indicators: Danaher's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Danaher's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-0.95%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>16.62%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Danaher's ROE excels beyond industry benchmarks, reaching <strong>1.9%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Danaher's ROA excels beyond industry benchmarks, reaching <strong>1.22%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Danaher's debt-to-equity ratio is below the industry average. With a ratio of <b>0.32</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Danaher Stock

<p>Ratings for Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) were provided by 26 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $195.42, a high estimate of $260.00, and a low estimate of $125.00. Observing a downward trend, the current average is 2.83% lower than the prior average price target of $201.12. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242437_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Texas Instruments is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>James Schneider</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$225.00</td>
<td>-</td>
</tr>
<tr>
<td>John Vinh</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$171.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kevin Garrigan</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$216.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$125.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Texas Instruments. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Texas Instruments compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Texas Instruments's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Texas Instruments's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TXN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Texas Instruments analyst ratings.</strong></a></p>
<h2>About Texas Instruments</h2>
<p>Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.</p>
<h3>Understanding the Numbers: Texas Instruments's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Texas Instruments's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of <strong>11.14%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Texas Instruments's net margin is impressive, surpassing industry averages. With a net margin of <strong>28.98%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Texas Instruments's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.08%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Texas Instruments's ROA excels beyond industry benchmarks, reaching <strong>3.4%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.78</strong>, Texas Instruments faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Texas Instruments Stock: A Deep Dive Into Analyst Perspectives (26 Ratings)

<p><strong>Charter Communications's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NYSE">CHTR</a>) short percent of float has risen 6.32% since its last report. The company recently reported that it has <strong>12.42 million shares sold short</strong>, which is 16.99% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 9.93 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Charter Communications Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242435_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Charter Communications has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Charter Communications's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Charter Communications's peer group average for short interest as a percentage of float is 15.12%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

CHTR

Is the Market Bullish or Bearish on Charter Communications?

<p><strong>Diebold Nixdorf's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>) short percent of float has fallen 6.07% since its last report. The company recently reported that it has <strong>832 thousand shares sold short</strong>, which is 4.33% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.46 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Diebold Nixdorf Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242430_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Diebold Nixdorf has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Diebold Nixdorf's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Diebold Nixdorf's peer group average for short interest as a percentage of float is 11.13%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


How Is The Market Feeling About Diebold Nixdorf?

<p>In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $952.29, with a high estimate of $1135.00 and a low estimate of $700.00. Observing a downward trend, the current average is 8.26% lower than the prior average price target of $1038.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242428_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$942.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1135.00</td>
<td>$1133.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$936.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$700.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$928.00</td>
<td>$973.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eli Lilly. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Eli Lilly's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Eli Lilly's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Eli Lilly analyst ratings.</strong></a></p>
<h2>About Eli Lilly</h2>
<p>Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.</p>
<h3>Eli Lilly: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Eli Lilly showcased positive performance, achieving a revenue growth rate of <strong>45.17%</strong> as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>21.68%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Eli Lilly's ROE excels beyond industry benchmarks, reaching <strong>18.42%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Eli Lilly's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.28%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.44</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts

<p><strong>Caterpillar's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) short percent of float has risen 3.08% since its last report. The company recently reported that it has <strong>6.30 million shares sold short</strong>, which is 1.34% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.12 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Caterpillar Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1752242424_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Caterpillar has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Caterpillar's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Caterpillar's peer group average for short interest as a percentage of float is 6.04%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


What's Driving the Market Sentiment Around Caterpillar?

Press Releases

UMAMI Bioworks and Steakholder Foods Join Forces to Scale 3D-Printed Fish Fillets for Global Commercialization

Contracts

Steakholder Foods® to Sell MX200 Printer to Vegefarm for Asia Market Launch

Steakholder Foods to Present at the 27th Annual ICR Conference

Steakholder Foods Shares Letter from CEO Arik Kaufman

Steakholder Foods® Secures $250,000 in Third SIIRD Grant Installment

Steakholder Foods® Announces $1.25 Million Private Placement and $8 Million Equity Line of Credit Funding Mechanism

Steakholder Foods Reports 2024 Financial Results and Provides Business Update

Steakholder Foods Announces ADS Ratio Adjustment

Steakholder Foods Announces Signing of Investment and Convertible Loan Agreements, and Memorandum of Understanding for Proposed Transformative Acquisition of Twine Solutions

Power Metallic Mines (TSXV: PNPN | OTCQB: PNPNF) Issues Summer 2025 "BIG Picture" Exploration Update – More Stocks Inside

AIRI

BTCM

CGTX

PNPNF

SAFX

SNYR

STKH

TSXV:PNPN

Branchout Food

Australian Oilseeds Holdings Limited - Ordinary Shares

Australian Oilseeds Hldgs

Farmmi

CIMG

Coffee Holding Co

Moolec Science

Oriental Rise Holdings Limited - Ordinary Shares

Oriental Rise Holdings

TDH Hldgs

Planet Green Holdings

Rocky Mountain Chocolate Factory, Inc. - Common Stock

Rocky Mountain Chocolate

Sow Good

SRX HealthSolutions

Steakholder Foods Ltd. - American Depositary Shares

Top Wealth Group Holding Limited - Class A Ordinary Shares

Comments

Steakholder Foods

Actualités

Dernières nouvelles pour Steakholder Foods (NASDAQ:STKH) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL